Role of residue 87 in the activity and regioselectivity of clozapine metabolism by drug-metabolizing CYP102A1 M11H: Application for structural characterization of clozapine GSH conjugates

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2411-2420

  Rea, Vanina ^a   Dragovic, Sanja ^a   Boerma, Jan Simon ^a   De Kanter, Frans J J ^a   Vermeulen, Nico P E ^a   Commandeur, Jan N M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 BM3; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; HISTIDINE; METHIONINE; RECOMBINANT ENZYME;

ARTICLE; BIOCATALYST; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVATION; DRUG METABOLISM; DRUG OXIDATION; MUTANT; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; GLUTATHIONE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY;

EID: 81855173536     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041046     Document Type: Article

References (27)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
2. Buchanan RW (1995) Clozapine: efficacy and safety. Schizophr Bull 21:579-591.
3. Carmichael AB and Wong LL (2001) Protein engineering of Bacillus megaterium CYP102A1. The oxidation of polycyclic aromatic hydrocarbons. Eur J Biochem 268:3117-3125.
4. Damsten MC, van Vugt-Lussenburg BM, Zeldenthuis T, de Vlieger JS, Commandeur JN, and Vermeulen NP (2008) Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 171:96-107. (Pubitemid 350191849)
5. Dragovic S, Boerma JS, van Bergen L, Vermeulen NP, and Commandeur JN (2010) Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine. Chem Res Toxicol 23:1467-1476.
6. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
7. Fischer V, Haar JA, Greiner L, Lloyd RV, and Mason RP (1991) Possible role of free radical formation in clozapine (clorazil) induced agranulocytosis. Mol Pharmacol 40:846-853.
8. Habig WH, Pabst MJ, and Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139.
9. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, and Fleischhacker WW (1997) Hepatotoxicity of clozapine. J Clin Psychopharmacol 17:314-317. (Pubitemid 27312431)
10. Kim KH, Kang JY, Kim DH, Park SH, Park SH, Kim D, Park KD, Lee YJ, Jung HC, Pan JG, et al. (2011) Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants. Drug Metab Dispos 39:140-150.
11. Landwehr M, Hochrein L, Otey CR, Kasrayan A, Bäckvall JE, and Arnold FH (2006) Enantio-selective alpha-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J Am Chem Soc 128:6058-6059.
12. Li QS, Ogawa J, Schmid RD, and Shimizu S (2001) Engineering cytochrome P450 BM-3 for oxidation of polycyclic aromatic hydrocarbons. Appl Environ Microbiol 67:5735-5739. (Pubitemid 33641012)
13. Liu ZC and Uetrecht JP (1995) Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 275:1476-1483.
14. Lussenburg BM, Babel LC, Vermeulen NP, and Commandeur JN (2005) Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. Anal Biochem 341:148-155. (Pubitemid 40615731)
15. Madsen KG, Olsen J, Skonberg C, Hansen SH, and Jurva U (2007) Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism. Chem Res Toxicol 20:821-831. (Pubitemid 46953690)
16. Maggs JL, Williams D, Pirmohamed M, and Park BK (1995) The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 275:1463-1475.
17. Ost TW, Miles CS, Murdoch J, Cheung Y, Reid GA, Chapman SK, and Munro AW (2000) Rational re-design of the substrate binding site of flavocytochrome P450 BM3. FEBS Lett 486:173-177.
18. Pirmohamed M, Williams D, Madden S, Templeton E, and Park BK (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984-990.
19. Safferman A, Lieberman JA, Kane JM, Szymanski S, and Kinon B (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17:247-261.
20. Sawayama AM, Chen MM, Kulanthaivel P, Kuo MS, Hemmerle H, and Arnold FH (2009) A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry 15:11723-11729.
21. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
22. Smith DA and Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol. 22:267-279.
23. Tugnait M, Hawes EM, McKay G, Eichelbaum M, and Midha KK (1999) Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem-Biol Interact 118:171-189. (Pubitemid 29179541)
24. van Vugt-Lussenburg BM, Stjernschantz E, Lastdrager J, Oostenbrink C, Vermeulen NP, and Commandeur JN (2007) Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J Med Chem 50:455-461. (Pubitemid 46239780)
25. Vottero E, Rea V, Lastdrager J, Honing M, Vermeulen NP, and Commandeur JN (2011) Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11. J Biol Inorg Chem 16:899-912.
26. Wagstaff A and Perry C (2003) Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs 17:273-280 (Pubitemid 36390411)
27. Yun CH, Kim KH, Kim DH, Jung HC, and Pan JG (2007) The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol 25:289-298. (Pubitemid 46899248)